Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
2 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
4 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
6 Adrenergic signaling in cardiomyocytes 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
7 Adrenergic signaling in cardiomyocytes 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
11 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
12 Alcoholism 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
13 Alcoholism 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
14 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
15 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
16 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
17 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
18 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
20 AMPK signaling pathway 💬
 1件: ADRA1A 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
21 AMPK signaling pathway 💬
 1件: ADRA1A 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
22 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
23 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
24 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
25 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
26 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
27 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
28 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
29 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
30 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
31 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
32 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
33 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
34 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
36 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
37 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
38 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
39 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
40 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
41 Bile secretion 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
42 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
43 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
44 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
45 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
46 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
47 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
48 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
49 Calcium signaling pathway 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
50 Calcium signaling pathway 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
51 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
52 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
53 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
54 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
55 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
56 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
57 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
58 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
59 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
60 cGMP-PKG signaling pathway 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
61 cGMP-PKG signaling pathway 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
62 cGMP-PKG signaling pathway 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 13件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 💬
63 cGMP-PKG signaling pathway 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D01205 💬 Dexmedetomidine 13件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 💬
64 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
65 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
66 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
67 Chemical carcinogenesis - reactive oxygen species 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
68 Chemical carcinogenesis - reactive oxygen species 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
69 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
70 Chemical carcinogenesis - receptor activation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
71 Chemical carcinogenesis - receptor activation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
72 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
73 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
74 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
75 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
76 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
77 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
78 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
79 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
80 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
81 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
82 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
83 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
84 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
85 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
86 Complement and coagulation cascades 💬
 1件: SERPINC1 💬 D07510 💬 Heparin 12件: 47, 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 💬
87 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
88 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
89 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
90 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
91 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
92 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
93 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
94 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
95 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
96 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
97 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
98 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
99 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
100 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
101 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
102 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
103 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
104 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
105 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
106 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
107 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
108 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
109 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
110 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
111 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
112 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
113 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
114 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
115 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
116 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
117 Focal adhesion 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
118 Focal adhesion 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
119 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
120 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
121 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
122 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
123 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
124 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
125 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
126 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
127 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
128 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
129 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
130 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
131 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
132 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
133 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
134 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
135 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
136 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
137 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
138 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
139 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
140 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
141 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
142 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
143 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
144 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
145 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
146 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
147 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
148 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
149 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
150 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
151 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
152 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
153 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
154 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
155 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
156 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
157 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
158 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
159 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
160 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
161 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
162 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
163 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
164 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
165 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
166 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
167 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
168 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
169 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
170 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
171 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
172 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
173 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
174 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
175 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
176 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
177 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
178 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
179 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
180 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
181 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
182 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
183 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
184 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
185 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
186 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
187 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
188 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
189 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
190 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
191 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
192 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
193 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
194 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
195 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
196 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
197 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
198 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
199 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
200 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
201 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
202 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
203 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
204 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
205 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
206 Metabolic pathways 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
207 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
208 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
209 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
210 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
211 Morphine addiction 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
212 Morphine addiction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
213 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
214 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
215 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
216 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
217 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
218 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
219 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
220 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
221 Neuroactive ligand-receptor interaction 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
222 Neuroactive ligand-receptor interaction 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
223 Neuroactive ligand-receptor interaction 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 13件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 💬
224 Neuroactive ligand-receptor interaction 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D01205 💬 Dexmedetomidine 13件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 💬
225 Neuroactive ligand-receptor interaction 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
226 Neuroactive ligand-receptor interaction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
227 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
228 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
229 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
230 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
231 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
232 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
233 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
234 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
235 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
236 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
237 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
238 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
239 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
240 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
241 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
242 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
243 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
244 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
245 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
246 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
247 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
248 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
249 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
250 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
251 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
252 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
253 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
254 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
255 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
256 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
257 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
258 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
259 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
260 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
261 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
262 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
263 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
264 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
265 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
266 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
267 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
268 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
269 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
270 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
271 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
272 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
273 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
274 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
275 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
276 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
277 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
278 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
279 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
280 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
281 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
282 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
283 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
284 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
285 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
286 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
287 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
288 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
289 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
290 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
291 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
292 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
293 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
294 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
295 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
296 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
297 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
298 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
299 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
300 Salivary secretion 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
301 Salivary secretion 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
302 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
303 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
304 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
305 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
306 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
307 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
308 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
309 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
310 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
311 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
312 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
313 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
314 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
315 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
316 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
317 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
318 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
319 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
320 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
321 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
322 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
323 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
324 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
325 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
326 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
327 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
328 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
329 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
330 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
331 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
332 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
333 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
334 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
335 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
336 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
337 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
338 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
339 Vascular smooth muscle contraction 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D00680 💬 Methylergometrine 3件: 118, 280, 288 💬
340 Vascular smooth muscle contraction 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 3件: 118, 280, 288 💬
341 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
342 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
343 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
344 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
345 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
346 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
347 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
348 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
349 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ